Stay updated with breaking news from Jeff Settleman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pfizer is investing US$25m in a US developer of live biotherapeutics, Vedanta Biosciences; that project is one of four investments, totaling US$120m, made by Pfizer in the second half of 2020 under its breakthrough growth program focused on clinical stage biotech companies of potential future strategic interest to the pharma giant.
These updates are republished press releases and communications from members of the Science|Business Network Pfizer invests $120M in four biotechnological innovation companies Pfizer Inc. today announced that, during the second half of 2020, it invested a total of $120 million in four clinical-stage biotech companies as part of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is investing up to $500 million in biotechnology companies, providing funding and access to Pfizer’s scientific expertise to help ensure the continuity of promising clinical development programs...
First four investments of new program created to support clinical-stage biotechnology companies New investments include companies focused on Oncology,...